Amplyx Pharmaceuticals, Inc.
APX001, a first-in-class small molecule Gwt1 synthase inhibitor prodrug for treating invasive fungal infections
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Latest Form D
- $40M, Aug 2017
- Total capital
- $72.4M
- Federal grants
- $8.1M
- 8 awards · 2015–2018
- Rank in peer group#73 of 514
- Private capital raised
- $61.5M
- 3 Form D · last Aug 2017
- 111 months since last filing
- Federal contracts
- $2.7M
- 1 award · Defense
- Rank in Biotech#117 of 4373
- Granted patents
- 3
- 19 pending · first 2018
- Rank in peer group#109 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Developing a novel antifungal targeting Gwt1 for the treatment of invasive aspergillosis and rare mold infections$726K
- Federal contractDefense · Igf::ot::igf Clinical Trial$2.7M
- Federal grantHealth and Human S · Phase II · Developing a novel antifungal targeting Gwt1 for the treatment of invasive aspergillosis and rare mold infections$1.5M
- Private capital raisedForm D · SEC · 3rd filing$40M
- Federal grantHealth and Human S · Phase II · Developing a Novel, Fungicidal Therapeutic to Treat Coccidioidomycosis$732K
- Federal grantHealth and Human S · Phase II · Developing a Novel Fungicidal Therapeutic to Treat Coccidioidomycosis$1.5M
- Federal grantHealth and Human S · Phase II · Developing a New Therapeutic for the Treatment of Invasive Aspergillosis$745K
- Private capital raisedForm D · SEC · 2nd filing$20M
- Private capital raisedForm D · SEC · 1st filing$1.5M
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · A Computer Modeling Approach$749K
- Federal grantHealth and Human S · Phase II · Developing a New Therapeutic for the Treatment of Invasive Aspergillosis$1.5M
- Federal grantHealth and Human S · Phase II · A Combination Therapy Approach to Treating Drug Resistant Fungal Infections$751K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
4months
from Amplyx Pharmaceuticals, Inc.’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $751K
- First Form D · Aug 2015
- $1.5M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#73 · top 14%
- Granted patents#109 · top 21%
- Linked publications#21 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mitchell MutzResearcherExecutive OfficerLinked by $751K in grants as PI
- Alan FuhrmanExecutive OfficerNamed in SEC Form D filings
- Anand MehraDirectorNamed in SEC Form D filings
- Chrysa MineoDirectorNamed in SEC Form D filings
- Ciara KennedyExecutive Officer, DirectorNamed in SEC Form D filings
- Ed MathersDirectorNamed in SEC Form D filings
Show all 17 people
- Edward MathersDirectorNamed in SEC Form D filings
- Elaine HeronDirectorNamed in SEC Form D filings
- Jack FlorioDirectorNamed in SEC Form D filings
- Johan KordelDirectorNamed in SEC Form D filings
- Johan K?rdelDirectorNamed in SEC Form D filings
- Karen TalmadgeDirectorNamed in SEC Form D filings
- Michael GreyExecutive Officer, DirectorNamed in SEC Form D filings
- Mike HodgesExecutive OfficerNamed in SEC Form D filings
- Niall ODonnellDirectorNamed in SEC Form D filings
- Paul GrintDirectorNamed in SEC Form D filings
- Santosh VetticadenDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 22- GrantedPyridine Derivatives Substituted By Heterocyclic Ring And Amino GroupUSPTOUS 11,771,688
- GrantedHeterocycle Substituted Pyridine Derivative Antifungal AgentsUSPTOUS 11,512,079
- GrantedAntifungal CompoundsUSPTOUS 9,956,207
Show all 22 patent records
- Pyridine Derivatives Substituted By Heterocyclic Ring And Amino GroupOct 3, 2023 · US 11,771,688Granted
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsNov 29, 2022 · US 11,512,079Granted
- Antifungal CompoundsMay 1, 2018 · US 9,956,207Granted
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsApplication PCTUS2020036400Pending
- Use Of Compounds In The Treatment Of Fungal InfectionsApplication 62985274Pending
- Compounds And Methods For Treating Fungal InfectionsApplication PCTUS2019049223Pending
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsApplication 62858897Pending
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsApplication PCTUS2018064609Pending
- Compounds And Methods For Treating Fungal InfectionsApplication 62725971Pending
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsApplication 62649225Pending
- Heterocycle Substituted Pyridine Derivative Antifungal AgentsApplication 62595894Pending
- Antifungal CompoundsApplication PCTUS2015011247Pending
- Antifungal AgentsApplication PCTUS2011054371Pending
- Therapeutic Agents Having Reduced ToxicityApplication PCTUS2011032175Pending
- Protease InhibitorsApplication PCTUS2010035025Pending
- Protease InhibitorsApplication PCTUS2009006600Pending
- AntimicrobialsApplication PCTUS2009006343Pending
- Enhancing The Efficacy Of Anti- Infective TherapeuticsApplication PCTUS2008012130Pending
- Compounds And Methods For Treating Fungal InfectionsApplication PCTUS2021037578Pending
- Improving The Pharmacokinetics Of Protease Inhibitors And Other DrugsApplication PCTUS2006043400Pending
- Use Of Compounds In The Treatment Of Fungal InfectionsApplication PCTUS2021020471Pending
- Compounds And Methods For Treating Fungal InfectionsApplication 63040450Pending
Recent research by its founders
- Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents20252 cites
- Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers202349 cites
- The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections202259 cites
Related companies, and why
- SYNVITROBIO, INC.Similar federal contract value in Biotech · $2.8M in contracts
- EPIBONE, INC.Similar federal contract value in Biotech · $2.8M in contracts
- AGILE SCIENCES, INC.Similar federal contract value in Biotech · $2.7M in contracts
- TECHNOVAX INCSimilar federal contract value in Biotech · $2.7M in contracts
- OMICSCRAFT LLCSimilar federal contract value in Biotech · $2.7M in contracts
- RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLCSimilar federal contract value in Biotech · $2.6M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .